NAMS logo

NEWAMSTERDAM PHARMA CO NV

NAMSNASDAQ
🏆 #1773 by market capEarnings Nov 3 · PreUS Equity
$222.49▲ $19.31 (+8.68%)
Simulated price
🔔
Track NAMS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.76B
Small Cap
📈Revenue Growth (YoY)
-50.6%
Declining
📊Gross Margin
92.2%
High
💵FCF Margin
-2018.3%
Thin
⚖️P/S Ratio
387.1x
Expensive
Otter Score
76
Good
No chart data available for NAMS.

Trading Snapshot

Day Range
$221.76 – $224.07
52-Week Range
$21.02 – $42.21
Volume
$1.75B
Avg Volume
$1.50B
Shares Outstanding
116.9M
Next Earnings
Nov 22, 2026

Fundamentals Snapshot

Annual Revenue
$23M
Last Q Revenue
$4M
P/E Ratio
-10.8
P/S Ratio
387.1x
EPS (TTM)
$-2.10
Dividend Yield
0.00%
Dilution (1yr)
+17.9%

Why Investors Own NAMS

  • ✓High-growth profile — revenue up +41.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NAMS logo

NEWAMSTERDAM PHARMA CO NV

NAMS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$23M▼ −50.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.7%▼ −0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$226M▲ +28.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$148M▼ −7.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
114.4M▲ +17.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$490M▼ −$281M YoY
StockOtter · stockotter.space

About NEWAMSTERDAM PHARMA CO NV

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$255.04
▲ +14.6% Upside
High Target$320.59
Low Target$191.97
Based on 20 analysts

Latest News & Updates

🚀
Reuters·2h ago

NEWAMSTERDAM PHARMA CO NV tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift NAMS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

NEWAMSTERDAM PHARMA CO NV announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.